IDEAYA: IND Clearance Enabling Phase 1/2 Trial for Combo in MTAP-Deletion Solid Tumors

 

• IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid tumors
• Potential first-in-class synthetic lethality combination targets mechanistically complementary nodes of the MTAP methylation pathway – MAT2A and PRMT5
• Compelling preclinical anti-tumor efficacy presented at AACR 2023 with durable CRs for IDE397 / AMG 193 combination, each at doses below maximally efficacious dose

https://www.biospace.com/article/releases/ideaya-announces-ind-clearance-enabling-phase-1-2-clinical-trial-for-combination-of-ide397-and-amg-193-in-mtap-deletion-solid-tumors/